

Annual Report

2020



Mark Suzman visits the Desmond Tutu HIV Foundation Research Site in Cape Town, South Africa on February 7, 2020.

Letter from the CEO

Globally, 2020 began as one of the healthiest years on record. Decades of work to strengthen primary care infrastructure, combat the spread of infectious diseases, and improve nutritional outcomes had helped to provide more people than ever before with the opportunity to lead healthy and productive lives.

By mid-year, COVID-19 had upended much of that progress around the world. What started as an acute health crisis quickly permeated all facets of life, with far-reaching social and economic consequences. Hard-earned gains in all spheres of development—not just global health, but also economic growth, education, and poverty alleviation—stalled or regressed.

On the backdrop of that turmoil, the murders of Black people in the United States, including George Floyd, Breonna Taylor, and Ahmaud Arbery, sparked a global movement to confront injustice and inequality. The spate of hate-based attacks against Asians throughout the year only heightened the urgency of that cause.

For many, 2020 will forever be linked with trauma and hardship. The number of lives lost and pain endured was staggering. But that will not be the year's only legacy.

It was also a year when we collectively adapted to the unfamiliar and found new ways to carry out our important work, even amidst the most trying of circumstances. A year when the institutions we built, nurtured, and resourced together with our partners for moments like this rose to the challenge. And a year when unprecedented collaboration between scientists around the world produced the fastest vaccine turnaround time in history.

Our close partnerships with you—the tireless advocates and dedicated professionals across the public, private, and philanthropic sectors—were indispensable to each of those successes. Those partnerships will continue to be integral as we work together to bring the pandemic under control and rebuild a more equitable and resilient world. As we strive to do so, we remain committed to transparency, accountability, and responsible stewardship of the financial resources generously entrusted to us.

To that end, I am pleased to share with you the Bill & Melinda Gates Foundation's 2020 Annual Report. Our complete audited financial statements are available on [gatesfoundation.org](https://www.gatesfoundation.org) and provide a clear and comprehensive picture of our ongoing efforts to carry out that stewardship.

This commitment is essential to achieve the impact we seek. Through judicious use of our resources, we can ensure that as much of it as possible goes toward reducing poverty, disease, and inequality.

It is an honor to join forces in that endeavor with our outstanding friends, partners, and grantees across the United States and around the world. To all of you, I extend my deepest thanks.



Mark Suzman

Chief Executive Officer

Bill & Melinda Gates Foundation

Funding summary

In 2020, the foundation provided US\$5.822 in direct grantee support in the following areas.

A. Global Development

B. Global Health


C. United States Program

D. Global Growth & Opportunity

E. Global Policy & Advocacy

F. Other Charitable Programs

G. Gender Equality



* Financial figures are rounded to the nearest million and include grants and direct charitable expenses (DCE), but not Program Related Investments (PRIs), for year ended December 31, 2020. Amounts in U.S. dollars.

Total direct grantee support

\$5.822 billion*

Program areas:

Global Development	\$1,893,000,000
Global Health	\$1,792,000,000
United States Program	\$642,000,000
Global Growth & Opportunity	\$620,000,000
Global Policy & Advocacy	\$523,000,000
Gender Equality	\$94,000,000

Non-program areas:

Other Charitable Programs	\$258,000,000
---------------------------	---------------

Global Development

\$1,893,000,000*

Polio	\$616,000,000
Global Delivery Programs	\$524,000,000
Family Planning	\$253,000,000
Maternal Newborn & Child Health	\$122,000,000
Africa Offices	\$109,000,000
India Office	\$108,000,000
Nutrition	\$107,000,000
Multilateral Partnerships	\$25,000,000
Emergency Response	\$22,000,000
Global Development Special Initiatives	\$7,000,000

Global Health

\$1,792,000,000*

Malaria	\$263,000,000
Vaccine Development	\$220,000,000
HIV	\$196,000,000
Innovative Technology Solutions	\$167,000,000
Discovery & Translational Sciences	\$165,000,000
Maternal, Newborn & Child Health Discovery & Tools	\$137,000,000
Tuberculosis	\$134,000,000
Pneumonia	\$110,000,000
Global Health Special Initiatives	\$99,000,000
Neglected Tropical Diseases	\$95,000,000
Enteric and Diarrheal Diseases	\$92,000,000
Integrated Development	\$78,000,000
Innovation Introduction	\$36,000,000

United States Program

\$642,000,000*

K-12 Education	\$329,000,000
Postsecondary Success	\$125,000,000
Washington State	\$47,000,000
U.S. Economic Mobility & Opportunity	\$45,000,000
United States Program Special Initiatives	\$37,000,000
Pathways	\$24,000,000
Scholarships	\$23,000,000
Early Learning	\$12,000,000

Global Growth & Opportunity

\$620,000,000*

Agricultural Development	\$383,000,000
Financial Services for the Poor	\$131,000,000
Water, Sanitation & Hygiene	\$101,000,000
Global Growth & Opportunity Special Initiatives	\$5,000,000

Global Policy & Advocacy

\$523,000,000*

Global Fund Core Contributions	\$247,000,000
Global Program Advocacy & Communications**	\$59,000,000
Philanthropic Partnerships	\$52,000,000
U.S. Program Advocacy & Communications**	\$48,000,000
Donor Government Relations	\$40,000,000
Tobacco Control	\$28,000,000
Development Policy & Finance	\$26,000,000
China Office	\$20,000,000
Global Policy & Advocacy Special Initiatives	\$3,000,000

Other Charitable Programs

\$258,000,000*

Gender Equality

\$94,000,000*

Gender Equality	90,000,000
Gender Equality Special Initiatives	4,000,000

* Financial figures are rounded to the nearest million and include grants and direct charitable expenses (DCE), but not Program Related Investments (PRIs), for year ended December 31, 2020. Amounts in U.S. dollars.

** Amount does not include advocacy and policy spending specific to individual strategies.